Diagnosis and Management of Gynecomastia for Urologists

Men's Health (A Dabaja, Section Editor)
  • 25 Downloads
Part of the following topical collections:
  1. Topical Collection on Men’s Health

Abstract

Purpose of Review

Our aim is to review the steps of diagnosis and management of gynecomastia with a special focus on treatment of gynecomastia associated with androgen deprivation therapy for prostate cancer.

Recent Findings

Recent studies investigating tamoxifen and radiation therapy for both therapy and prophylaxis of bicalutamide-induced gynecomastia are reviewed.

Summary

Gynecomastia is a common clinical problem, affecting between one and two thirds of middle-aged men. Diagnosis is typically made by history and physical exam. Common causes include chronic medical conditions and medications; however, unexplained gynecomastia should prompt laboratory work-up, followed by appropriate imaging studies to evaluate for hormone producing cancers. For patients taking bicalutamide for treatment of prostate cancer, tamoxifen or radiation therapy for gynecomastia are excellent options.

Keywords

Gynecomastia Prostate cancer Tamoxifen Androgen deprivation therapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Lee Baumgarten declares no potential conflicts of interest. Ali A. Dabaja is a section editor for Current Urology Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Sansone A, Romanelli F, Sansone M, Lenzi A, Di Luigi L. Gynecomastia and hormones. Endocrine. 2017;55:37–44.  https://doi.org/10.1007/s12020-016-0975-9.CrossRefPubMedGoogle Scholar
  2. 2.
    Cuhaci N, Polat S, Evranos B, Ersoy R, Cakir B. Gynecomastia: clinical evaluation and management. Indian J Endocrinol Metab. 2014;18:150–8.  https://doi.org/10.4103/2230-8210.129104.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ordaz D, Thompson J. Gynecomastia and psychological functioning: a review of the literature. Body Image. 2015;15:141–8.  https://doi.org/10.1016/j.bodyim.2015.08.004.CrossRefPubMedGoogle Scholar
  4. 4.
    Pusl T, Stoemmer P. Gynecomastia: look beyond the obvious. Am J Med. 2017;130:e439–40.  https://doi.org/10.1016/j.amjmed.2017.04.021.CrossRefPubMedGoogle Scholar
  5. 5.
    Yousef AJ. Male breast cancer: epidemiology and risk factors. Semin Oncol. 2017;44:267–72.  https://doi.org/10.1053/j.seminoncol.2017.11.002.CrossRefGoogle Scholar
  6. 6.
    Braunstein GD. Gynecomastia. N Engl J Med. 2007;357:1229–37.  https://doi.org/10.1056/NEJMcp070677.CrossRefPubMedGoogle Scholar
  7. 7.
    Doyle S, Steel J, Porter G. Imaging male breast cancer. Clin Radiol. 2011;66:1079–85.  https://doi.org/10.1016/j.crad.2011.05.004.CrossRefPubMedGoogle Scholar
  8. 8.
    Evans G, Anthony T, Appelbaum AH, Schumpert TD, Levy KR, Amirkhan RH, et al. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg. 2001;181:96–101.  https://doi.org/10.1016/S0002-9610(00)00571-7.CrossRefPubMedGoogle Scholar
  9. 9.
    Bannayan G, Hajdu S. Gynecomastia: clinicopathologic study of 351 cases. Am J Clin Pathol. 1972;57:431–7.  https://doi.org/10.1093/ajcp/57.4.431.CrossRefPubMedGoogle Scholar
  10. 10.
    Sinclair M, Grossmann M, Gow PJ, Angus PW. Testosterone in men with advanced liver disease: abnormalities and implications. J Gastroenterol Hepatol. 2015;30:244–51.  https://doi.org/10.1111/jgh.12695.CrossRefPubMedGoogle Scholar
  11. 11.
    Iglesias P, Carrero JJ, Diez JJ. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol. 2012;25:31–42.  https://doi.org/10.5301/JN.2011.8481.CrossRefPubMedGoogle Scholar
  12. 12.
    Thompson DF, Carter JR. Drug-induced gynecomastia. Pharmacotherapy. 1993;13:37–45.  https://doi.org/10.1002/j.1875-9114.1993.tb02688.x.PubMedGoogle Scholar
  13. 13.
    • Ali SN, Jayasena CN, Sam AH. Which patients with gynaecomastia require more detailed investigation? Clin Endocrinol. 2018;88:360–3.  https://doi.org/10.1111/cen.13526. A recent, concise review of the management strategy for patients with gynecomastia and suspected underlying malignancy. CrossRefGoogle Scholar
  14. 14.
    Narula HS, Carlson HE. Gynaecomastia—pathophysiology, diagnosis and treatment. Nat Rev Endocrinol. 2014;10:684–98.  https://doi.org/10.1038/nrendo.2014.139.CrossRefPubMedGoogle Scholar
  15. 15.
    Rohrich RJ, Ha RY, Kenkel JM, Adams WP Jr. Classification and management of gynecomastia: defining the role of ultrasound-assisted liposuction. Plastic Reconstr Surg. 2003;111:909–23.  https://doi.org/10.1097/01.PRS.0000042146.40379.25.CrossRefGoogle Scholar
  16. 16.
    Hanavadi S, Banerjee D, Monypenny IJ, Mansel RE. The role of tamoxifen in the management of gynaecomastia. Breast. 2006;15:276–80.  https://doi.org/10.1016/j.breast.2005.04.007.CrossRefPubMedGoogle Scholar
  17. 17.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2014;65:467–79.  https://doi.org/10.1016/j.eururo.2016.08.002.CrossRefPubMedGoogle Scholar
  18. 18.
    Davanço RAS, Neto MS, Garcia ÉB, Matsuoka PK, Huijsmans JP, Ferreira LM. Quality of life in the surgical treatment of gynecomastia. Aesthet Plast Surg. 2009;33:514–7.  https://doi.org/10.1007/s00266-008-9213-z.CrossRefGoogle Scholar
  19. 19.
    • Nguyen P, Alibhai S, Shehzad B, D’Amico A, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–36.  https://doi.org/10.1016/j.eururo.2014.07.010. Up to date review of the clinical effectiveness of available treatment strategies for all side effects of ADT for prostate cancer. CrossRefPubMedGoogle Scholar
  20. 20.
    Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis. 2005;8:75–83.  https://doi.org/10.1038/sj.pcan.4500782.CrossRefPubMedGoogle Scholar
  21. 21.
    •• Serretta V, Altieri V, Morgia G, Nicolosi F, De Grande G, Mazza R, et al. A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia. Clin Genitourin Cancer. 2012;10:174–9.  https://doi.org/10.1016/j.clgc.2012.03.002. One hundred seventy-six patients with prostate cancer receiving bicalutamide monotherapy were randomized to receive tamoxifen therapeutically or prophylactically. Four percent of the therapeutic group discontinued bicalutamide due to painful gynecomastia, whereas no patients in the prophylactic group did. The authors conclude that bicalutamide-induced gynecomastia can be prevented to a significant degree by prophylaxis with tamoxifen. CrossRefPubMedGoogle Scholar
  22. 22.
    Tunio MA, Al-Asiri M, Al-Amro A, Bayoumi Y, Fareed M. Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia: results of a meta-analysis. Curr Oncol. 2012;19:280–8.  https://doi.org/10.3747/co.19.993.CrossRefGoogle Scholar
  23. 23.
    Widmark A, Fosså SD, Lundmo P, Damber JE, Vaage S, Damber L, et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology. 2003;61:145–51.  https://doi.org/10.1097/01.ju.0000069500.65586.e5.CrossRefPubMedGoogle Scholar
  24. 24.
    Boccardo F, Rubagotti A, Battaglia M, di Tonno P, Selvaggi FP, Conti G, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005;23:8–15.  https://doi.org/10.1200/JCO.2005.12.013.CrossRefGoogle Scholar
  25. 25.
    •• Wibowo E, Pollock PA, Hollis N, Wassersug RJ. Tamoxifen in men: a review of adverse events. Andrology. 2016;4:776–88.  https://doi.org/10.1111/andr.12197. Systematic review of adverse events of tamoxifen for men. It is a well-tolerated medication with less than 5% of men discontinue tamoxifen due to side effects. CrossRefPubMedGoogle Scholar
  26. 26.
    • Viani GA, Bernardes da Silva LG, Stefano EJ. Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy? Int J Radiat Oncol Biol Phys. 2012;83:e519–24.  https://doi.org/10.1016/j.ijrobp.2012.01.036. Meta-analysis of 6 trials with 777 patients shows that tamoxifen prophylaxis is about twice as effective (absolute risk reduction of 64%) as radiation prophylaxis (ARR of 30%) in preventing breast pain and gynecomastia. Authors conclude that radiation is an acceptable alternative for patients at high risk of tamoxifen induced cardiac side effects. CrossRefPubMedGoogle Scholar
  27. 27.
    Ozen H, Akyol F, Toktas G, Eskicorapci S, Unluer E, Kuyumcuoglu U, et al. Is prophylactic breast radiotherapy necessary in all patients with prostate cancer and gynecomastia and/or breast pain? J Urol. 2010;184:519–24.  https://doi.org/10.1016/j.juro.2010.03.137.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Henry Ford Health SystemDetroitUSA

Personalised recommendations